{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"64.500","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"153,278,691","primaryexch":"香港交易所","ric":"9887.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BQTYGN9","am":"19.30","iv":"","ew_strike":"","as":"62.950","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"62.400","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"57.450","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"康小強","underlying_ric":"9887.HK","hi52":"83.600","issuer_name":"南京維立志博生物科技股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"62.050","mkt_cap":"9.64","f_aum_hkd":null,"ew_sub_per_to":"","ls":"62.900","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-1.200","aum":"","issued_shares_class_B":null,"vo":"306.03","secondary_listing_flag":false,"listing_date":"2025年7月25日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"南京維立志博生物科技股份有限公司 - B - H股","nm_s":"維立志博－Ｂ","sym":"9887","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"南京維立志博生物科技股份有限公司是一家主要從事發現、開發和商業化治療腫瘤、自身免疫性疾病以及其他嚴重疾病的新療法的中國公司。該公司的主要候選藥物包括LBL-024、LBL-034、LBL-033、LBL-007等。該公司的LBL-024主要用于治療肺外神經內分泌癌（EP-NEC）、小細胞肺癌（SCLC）、膽道癌（BTC）及非小細胞肺癌（NSCLC）、食管鱗狀細胞癌（ESCC）、肝細胞癌（HCC）、胃癌（GC）及其他實體瘤。該公司还開發了專有技術平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他幾個雙特異性抗體及融合蛋白平台。該公司主要在國內市場開展業務。","op":"62.050","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國江蘇省南京市<br/>江北新區<br/>華康路122號<br/>加速器四期05棟","pc":"-1.87","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"64.100","isin":"CNE1000070H8","moneyness":""}},"qid":"1759074324905"}
